Back to search

Aristotle University Of Thessaloniki (AUTH)

Επίδραση της αναστολής της κυκλοοξυγενάσης-2 στην αναστόμωση του παχέος εντέρου σε επίμυες

Abstract

dc:description

Cyclooxygenase (COX) is an enzyme which catalyzes the conversion of arachidonic acid into prostaglandin derivatives. Two isoforms of COX have been identified, COX-1, which is constitutively expressed and COX-2, which is expressed in response to external stimuli and is postulated to be mainly involved in pathologic conditions such as inflammation, pain and fever. Based on these findings, a new group of non-steroid anti-inflammatory drugs (NSAIDs) emerged, the coxibs. The members of this group of drugs allow specific targeting of the inflammatory disease processes mediated by COX-2, without the disruption of normal homeostatic mechanisms which are mediated by COX-1. Numerous side effects previously assigned to NSA1D therapy such as gastric ulceration and increased bleeding tendency can be avoided. Recent evidence shows that selective COX-2 inhibitors exhibit antiangiogenic activity and are consequently used as chemoprevention against specific cancer types. The tissue healing process is also directly related to angiogenesis. Healing of intestinal anastomoses is of special interest to the surgeon because impaired healing of the anastomosis may lead to life threatening anastomotic dehiscence. The present study investigates whether COX-2 inhibition by celecoxib impairs the healing of colonic anastomosis in rats. Seventy two male Wistar rats were randomly assigned into two major groups (36 rats each), the study group and the control group. Each group was further divided into two subgroups (18 rats each) depending on the day of sacrifice (3rd or 7th postoperative day). All rats underwent anesthesia, laparotomy, resection of 1 cm of large intestine from a point approximately 3 cm proximal to the peritoneal reflection and construction of an end-to-end anastomosis using 6-8 inverting polypropylene 6/0 sutures. Celecoxib 10mg/kg body weight once daily was administered to rats of the study group, beginning from 2 days preoperatively and for the duration of the experiment. In the same manner, placebo treatment was administered to rats of the control group. Animals were killed either 3 or 7 days after the operation, assessed for adhesion formation and colonic wound strength by means of bursting pressure measurement. Additionally, the point of rupture during the bursting pressure measurement was recorded. Anastomoses were opened and divided longitudinally into two equal parts. One half of the anastomosis was stained with hematoxylin and eosin in order to assess inflammatory cell composition and fibroblast reaction. Sections obtained from the anastomosis were subjected to immunohistochemistry with CD34 to evaluate microvessel formation. The other half was subjected to biochemical determination of MMP-2 and MMP-9 (zymography), proMMP-2, TlMP-1 and VEGF concentrations (ELISA). Further division of these specimens was undertaken in order to differentiate the anastomotic tissue from the normal tissue taken from the area just next to the anastomosis. Mean body weight decreased in the early postoperative period, but steadily increased during postoperative days 3 to 7 and reached the preoperative levels in groups sacrificed on postoperative day 7. No significant differences were found between study and control groups. Macroscopic assessment of adhesion formation revealed significantly fewer adhesions in study groups and especially in rats sacrificed on postoperative day 7, corresponding to the fact that those rats were exposed for longer time period to the antiangiogenic drug of the present study. No evident anastomotic dehiscence was found in all groups. Bursting pressure measurement showed a moderate decrease in rats that had received celecoxib, but without statistically significant differences between groups. The anastomotic strength increased on day 7 in both study and control groups. A shift was noted regarding the anastomotic rupture site. The anastomotic area was the site of rupture for the majority of rats sacrificed on postoperative day 3, but on day 7 the rupture mostly occurred away from the anastomosis, reflecting the increased anastomotic strength. Biochemical tissue analysis with zymography showed statistically significant reduction of the gelatin-degrading activity in rats that had received celecoxib, both in tissue samples from the anastomotic site and from areas next to the anastomosis. Interestingly, gelatine-degrading activity measured in anastomoses of the control group was significantly higher in samples from the anastomotic site than those from areas next to the anastomosis. Tissue concentration of proMMP-2 measured with ELISA revealed a significant reduction in rats that had received celecoxib, both in tissue samples from the anastomotic site and from areas next to the anastomosis. Similar results were noted when tissue concentration of VEGF was measured. On the other side, celecoxib did not affect tissue concentration of TIME-1. Histologic examination of sections originating from the anastomotic site stained with hematoxylin-eosin showed that the administration of celecoxib resulted in significant decrease of the inflammatory cell composition and fibroblast reaction compared to controls. The presence of newly formed microvessels, evaluated by CD34 immunohistochemistry, showed a small decrease in angiogenesis but without statistically significant differences between groups. Interpretation of these results leads to the conclusion that perioperative celecoxib administration results in reduction of the angiogenic process taking place on the healing anastomosis. Since MMPs are necessary for the degradation of vascular basal membrane facilitating endothelial cell migration and vessel formation, and VEGF is potent angiogenic promoter, the significantly lower levels of MMP and VEGF activity measured on samples originating from rats that had received celecoxib indicate suppression of angiogenesis. This antiangiogenic activity does not seem to alter the anastomotic strength which is measured by means of bursting pressure. We can therefore conclusively claim, based on the results of the present experimental study that the perioperative administration of celecoxib in colonic anastomosis rat model leads to reduction of parameters which reflect the angiogenic process on the anastomosis. This reduction however, does not correspond to impaired strength of the anastomosis which could lead to life threatening situations, such as anastomotic rupture and peritonitis.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2008

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Symeonidis, Nikolaos
  • Συμεωνίδης, Νικόλαος

Subjects

dc:subject × 20

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/25624

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Symeonidis, Nikolaos; Συμεωνίδης, Νικόλαος. Επίδραση της αναστολής της κυκλοοξυγενάσης-2 στην αναστόμωση του παχέος εντέρου σε επίμυες. Aristotle University Of Thessaloniki (AUTH), 2008. http://hdl.handle.net/10442/hedi/25624